Takeda Pharmaceutical Co (FRA:TKD) Valuation Rank


FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
65 GF Score
Price €29.25
GF Value €24.05
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Takeda Pharmaceutical Co Valuation Rank Related Terms

FRA:TKD
65GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €29.25 is trading 21.6% above its estimated GF Value™ of €24.05. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • Valuation Rank:
  • GF Value™: €24.05 vs. price of €29.25 (21.6% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score

Get the complete analysis for FRA:TKD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.25
Price
€24.05
GF Value